カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の腫瘍コンパニオン診断市場（2023-2030）：製品・サービス別、技術別（IHC、NGS）、疾患種類別（乳がん、白血病）、エンドユーザー別、地域別

【英語タイトル】Oncology Companion Diagnostic Market Size, Share & Trends Analysis Report By Product & Service, By Technology (IHC, NGS), By Disease Type (Breast Cancer, Leukemia), By End Use, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV178）・商品コード：GRV23NOV178
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：183
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：臨床診断
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,324,600見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

腫瘍コンパニオン診断市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界の腫瘍コンパニオン診断市場規模は、2023年から2030年にかけて年平均成長率12.9%で拡大し、2030年には82億ドルに達する見込みです。コンパニオン診断薬によって重要なゲノム情報へのアクセスが拡大することで、情報に基づいた意思決定が可能となり、患者さんに的を絞った治療法の設計が可能となるため、包括的なゲノム検査や腫瘍コンパニオン診断薬の需要が高まります。

グリベック（イマチニブ）やハーセプチン（トラスツズマブ）など、処方前にコンパニオン診断（CDx）検査を必要とする薬剤の上市により、腫瘍コンパニオン診断の収益は増加しています。この成長は、臨床試験中の多数のCDxに関連するがん治療薬のために、将来も続くと予想されます。CDxは、治療のための独占的または包括的な検査としての機能以外に、臨床試験における参加者の選択時にも重要な役割を果たします。患者がバイオマーカーの標的を有していれば、新薬候補がより高い奏効率を示す可能性が高まるからです。

CDxの使用に関連する経済的インセンティブは、医薬品開発者に医薬品と診断テストを組み合わせることを促しています。しかし、診断薬メーカーは、一方では支払者／医療提供者から、他方では医薬品メーカーからの相反する要求に直面しています。また、規制機関も診断薬と医薬品の開発スケジュールを一致させるために厳しい政策をとっています。そのため、診断薬メーカーは、単一の診断薬と特定の薬剤のマッチングに焦点を当てるのではなく、CDx開発の範囲を広げることが期待されています。

腫瘍コンパニオン診断市場レポートハイライト

- CDx検査の採用率および使用率の増加により、2022年には製品分野が最大の市場シェアを獲得しました。

- CDxの承認率が大幅に上昇し、医薬品とCDxの共同開発への投資が増加することで、製品セグメントの収益が増加する見込みです。

- CDx検査に必要な培地、緩衝液、試薬、その他の消耗品は頻繁に使用・購入されるため、消耗品が製品セグメントの主要シェアを占めています。

- 免疫組織化学（IHC）は、コストと時間の有効性、小さな腫瘍型に対するIHC技術の適合性、ルーチンの腫瘍CDxにおけるIHCの高い採用率、IHCに関連する低い技術要件など、IHC技術が提供する利点により、技術セグメントの大部分を占めています。

- EGFR pharmDx Kits、ER/PR pharmDx Kits、HercepTest Kits、PD-L1 IHC 28-8 pharmDx、VENTANA PD-L1 (SP142) Assay、VENTANA ALK (D5F3) CDx Assay、VENTANA ALK IHC assayなど、FDAが承認したIHCベースのCDxアッセイが多数存在することも、IHCセグメント内の収益増加をもたらすと予想されます。

- 非小細胞肺がん（NSCLC）セグメントは2022年に市場を支配し、予測期間中もその優位性を維持する見込みです。

- NSCLCは、肺がん症例の約80%を占める肺がんのサブタイプです。米国がん協会（ACS）が発表したデータによると、2020年には米国で約228,820人の肺がん患者が新たに診断されると予測されています。

- 乳がんおよび白血病分野は、がん患者数の増加により大幅な成長が見込まれます。

- 病院セグメントが2022年に市場で最大のシェアを占め、病院でのがん診断検査件数の増加により、かなりの成長率を示すと予測されます。

- 2022年には北米が市場を席巻：この地域には多数のプレーヤーが存在し、がん治療においてFDA認可のCDxソリューションが多数存在するためです。

- 技術の進歩と経済状況の改善により、アジア太平洋地域が最も速い成長率で市場を牽引すると予測されます。

- 遺伝子バイオマーカーのモニタリングと発見に積極的に関与するコミュニティがアジア諸国に存在することが、市場にプラスの影響を与えると予測されます。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. 市場変動・動向・範囲
第4章. 世界の腫瘍コンパニオン診断市場：製品＆サービス別予測・動向分析
第5章. 世界の腫瘍コンパニオン診断市場：技術別予測・動向分析
第6章. 世界の腫瘍コンパニオン診断市場：疾患タイプ別予測・動向分析
第7章. 世界の腫瘍コンパニオン診断市場：エンドユーザー別予測・動向分析
第8章. 世界の腫瘍コンパニオン診断市場：地域別予測・動向分析
第9章. 競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product & Service
1.1.2. Technology
1.1.3. Disease type
1.1.4. End use
1.1.5. Regional scope
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product & service outlook
2.2.2. Technology outlook
2.2.3. Disease type outlook
2.2.4. End use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Oncology Companion Diagnostic Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Oncology Companion Diagnostic Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Oncology Companion Diagnostic: Product and Services estimates & Trend Analysis
4.1. Oncology Companion Diagnostic Market, By Product & Services Key Takeaways
4.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Product
4.3.1. Product and services market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2. Instrument
4.3.2.1. Instrument market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3. Consumable
4.3.3.1. Consumable market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4. Software
4.3.4.1. Software market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Service
4.4.1. Service market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Oncology Companion Diagnostic: Technology Estimates & Trend Analysis
5.1. Oncology Companion Diagnostic Market, By Technology Key Takeaways
5.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Polymerase Chain Reaction (PCR)
5.3.1. Polymerase chain reaction (PCR) market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Next-Generation Sequencing (NGS)
5.4.1. Next-generation sequencing (NGS) market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Immunohistochemistry (IHC)
5.5.1. Immunohistochemistry (IHC) market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. In Situ Hybridization (ISH)/ Fluorescence in Situ Hybridization (FISH)
5.6.1. In itu Hybridization (ISH)/ Fluorescence in Situ Hybridization (FISH) market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Other Technologies
5.7.1. Other technologies market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Oncology Companion Diagnostic: By Disease Type Estimates & Trend Analysis
6.1. Oncology Companion Diagnostic Market, By Disease Type Key Takeaways
6.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Breast Cancer
6.3.1. Breast cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Non-Small Cell Lung Cancer
6.4.1. Non-small cell lung cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Colorectal Cancer
6.5.1. Colorectal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Leukemia
6.6.1. Leukemia market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Melanoma
6.7.1. Melanoma market estimates and forecasts, 2018 to 2030 (USD Million)
6.8. Prostate Cancer
6.8.1. Prostate cancer market estimates and forecasts, 2018 to 2030 (USD Million)
6.9. Others
6.9.1. Other market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Oncology Companion Diagnostic: By End Use Estimates & Trend Analysis
7.1. Oncology Companion Diagnostic Market, By End Use Key Takeaways
7.2. Oncology Companion Diagnostic Market: Movement & Market Share Analysis, 2022 & 2030
7.3. Hospital
7.3.1. Hospital market estimates and forecasts, 2018 to 2030 (USD Million)
7.4. Pathology/Diagnostic Laboratory
7.4.1. Pathology/Diagnostic laboratory market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Academic Medical Center
7.5.1. Academic medical center market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Diagnostic Market: Regional Estimates & Trend Analysis
8.1. Regional Outlook
8.2. Oncology Companion Diagnostic Market by Region: Key Takeaways
8.3. North America
8.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.3.2. U.S.
8.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.3.3. Canada
8.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.2. Germany
8.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.3. France
8.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.4. Italy
8.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.5. Spain
8.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.6. Sweden
8.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.7. Norway
8.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.4.8. Denmark
8.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.2. China
8.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.3. India
8.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.4. Australia
8.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.5. Thailand
8.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.5.6. South Korea
8.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.6.2. Mexico
8.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.6.3. Argentina
8.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7. MEA
8.7.1. Saudi Arabia
8.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7.2. South Africa
8.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7.3. UAE
8.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
8.7.4. Kuwait
8.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.2.1. Agilent Technologies, Inc.
9.2.1.1. Company overview
9.2.1.2. Financial performance
9.2.1.3. Product benchmarking
9.2.1.4. Strategic initiatives
9.2.2. Illumina, Inc.
9.2.2.1. Company overview
9.2.2.2. Financial performance
9.2.2.3. Product benchmarking
9.2.2.4. Strategic initiatives
9.2.3. QIAGEN N.V.
9.2.3.1. Company overview
9.2.3.2. Financial performance
9.2.3.3. Product benchmarking
9.2.3.4. Strategic initiatives
9.2.4. Thermo Fisher Scientific, Inc.
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. F. Hoffmann-La Roche Ltd.
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. ARUP Laboratories
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Abbott
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Myriad Genetics, Inc.
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. bioMérieux SA
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Invivoscribe, Inc.
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives

List of Tables

Table 1 List of abbreviation
Table 2 North America oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 3 North America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 4 North America oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 5 North America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 6 North America oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 7 U.S. oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 8 U.S. oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 9 U.S. oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 10 U.S. oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 11 Canada oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 12 Canada oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 13 Canada oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 14 Canada oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 15 Europe oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 16 Europe oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 17 Europe oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 18 Europe oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 19 Europe oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 20 Germany oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 21 Germany oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 22 Germany oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 23 Germany oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 24 UK oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 25 UK oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 26 UK oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 27 UK oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 28 France oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 29 France oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 30 France oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 31 France oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 32 Italy oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 33 Italy oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 34 Italy oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 35 Italy oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 36 Spain oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 37 Spain oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 38 Spain oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 39 Spain oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 40 Denmark oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 41 Denmark oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 42 Denmark oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 43 Denmark oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 44 Sweden oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 45 Sweden oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 46 Sweden oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 47 Sweden oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 48 Norway oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 49 Norway oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 50 Norway oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 51 Norway oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 52 Asia Pacific oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 53 Asia Pacific oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 54 Asia Pacific oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 55 Asia Pacific oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 56 Asia Pacific oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 57 Japan oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 58 Japan oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 59 Japan oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 60 Japan oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 61 China oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 62 China oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 63 China oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 64 China oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 65 India oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 66 India oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 67 India oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 68 India oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 69 Australia oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 70 Australia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 71 Australia oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 72 Australia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 73 Thailand oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 74 Thailand oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 75 Thailand oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 76 Thailand oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 77 South Korea oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 78 South Korea oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 79 South Korea oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 80 South Korea oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 81 Latin America oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 82 Latin America oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 83 Latin America oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 84 Latin America oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 85 Latin America oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 86 Brazil oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 87 Brazil oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 88 Brazil oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 89 Brazil oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 90 Mexico oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 91 Mexico oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 92 Mexico oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 93 Mexico oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 94 Argentina oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 95 Argentina oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 96 Argentina oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 97 Argentina oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 98 Middle East and Africa oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 99 Middle East and Africa oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 100 Middle East and Africa oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 101 Middle East and Africa oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 102 Middle East and Africa oncology companion diagnostic market, by region, 2018 - 2030 (USD Million)
Table 103 South Africa oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 104 South Africa oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 105 South Africa oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 106 South Africa oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 111 UAE oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 112 UAE oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 113 UAE oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 114 UAE oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)
Table 115 Kuwait oncology companion diagnostic market, by product & service, 2018 - 2030 (USD Million)
Table 116 Kuwait oncology companion diagnostic market, by technology, 2018 - 2030 (USD Million)
Table 117 Kuwait oncology companion diagnostic market, by disease type, 2018 - 2030 (USD Million)
Table 118 Kuwait oncology companion diagnostic market, by end use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Oncology companion diagnostic: Market outlook
Fig. 9 Oncology companion diagnostic: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Oncology companion diagnostic market driver impact
Fig. 15 Oncology companion diagnostic market restraint impact
Fig. 16 Oncology companion diagnostic market strategic initiatives analysis
Fig. 17 Oncology companion diagnostic market: Product & service movement analysis
Fig. 18 Oncology companion diagnostic market: Product & service outlook and key takeaways
Fig. 19 Product market estimates and forecasts, 2018 - 2030
Fig. 20 Service market estimates and forecasts, 2018 - 2030
Fig. 21 Oncology companion diagnostic market: Technology movement analysis
Fig. 22 Oncology companion diagnostic market: Technology outlook and key takeaways
Fig. 23 Polymerase chain reaction (PCR) market estimates and forecasts, 2018 - 2030
Fig. 24 Next-generation sequencing (NGS) market estimates and forecasts, 2018 - 2030
Fig. 25 Immunohistochemistry (IHC) market estimates and forecasts, 2018 - 2030
Fig. 26 In situ hybridization (ISH)/ fluorescence in situ hybridization (FISH) market estimates and forecasts, 2018 - 2030
Fig. 27 Other technologies market estimates and forecasts, 2018 - 2030
Fig. 28 Oncology companion diagnostic market: Disease type movement analysis
Fig. 29 Oncology companion diagnostic market: Disease type outlook and key takeaways
Fig. 30 Breast cancer market estimates and forecasts, 2018 - 2030
Fig. 31 Non-small cell lung cancer market estimates and forecasts, 2018 - 2030
Fig. 32 Colorectal cancer market estimates and forecasts, 2018 - 2030
Fig. 33 Leukemia market estimates and forecasts, 2018 - 2030
Fig. 34 Melanoma market estimates and forecasts, 2018 - 2030
Fig. 35 Prostate cancer market estimates and forecasts, 2018 - 2030
Fig. 36 Others market estimates and forecasts, 2018 - 2030
Fig. 37 Oncology companion diagnostic market: End use movement analysis
Fig. 38 Oncology companion diagnostic market: End use outlook and key takeaways
Fig. 39 Hospital market estimates and forecasts, 2018 - 2030
Fig. 40 Pathology/Diagnostic laboratory market estimates and forecasts, 2018 - 2030
Fig. 41 Academic medical center market estimates and forecasts, 2018 - 2030
Fig. 42 Global oncology companion diagnostic market: Regional movement analysis
Fig. 43 Global oncology companion diagnostic market: Regional outlook and key takeaways
Fig. 44 North America market estimates and forecasts, 2018 - 2030
Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
Fig. 46 Canada market estimates and forecasts, 2018 - 2030
Fig. 47 Europe market estimates and forecasts, 2018 - 2030
Fig. 48 UK market estimates and forecasts, 2018 - 2030
Fig. 49 Germany market estimates and forecasts, 2018 - 2030
Fig. 50 France market estimates and forecasts, 2018 - 2030
Fig. 51 Italy market estimates and forecasts, 2018 - 2030
Fig. 52 Spain market estimates and forecasts, 2018 - 2030
Fig. 53 Denmark market estimates and forecasts, 2018 - 2030
Fig. 54 Sweden market estimates and forecasts, 2018 - 2030
Fig. 55 Norway market estimates and forecasts, 2018 - 2030
Fig. 56 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 57 Japan market estimates and forecasts, 2018 - 2030
Fig. 58 China market estimates and forecasts, 2018 - 2030
Fig. 59 India market estimates and forecasts, 2018 - 2030
Fig. 60 Australia market estimates and forecasts, 2018 - 2030
Fig. 61 Thailand market estimates and forecasts, 2018 - 2030
Fig. 62 South Korea market estimates and forecasts, 2018 - 2030
Fig. 63 Latin America market estimates and forecasts, 2018 - 2030
Fig. 64 Brazil market estimates and forecasts, 2018 - 2030
Fig. 65 Mexico market estimates and forecasts, 2018 - 2030
Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
Fig. 67 Middle East and Africa. market estimates and forecasts, 2018 - 2030
Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 70 UAE market estimates and forecasts, 2018 - 2030
Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030

★調査レポート[世界の腫瘍コンパニオン診断市場（2023-2030）：製品・サービス別、技術別（IHC、NGS）、疾患種類別（乳がん、白血病）、エンドユーザー別、地域別] (コード：GRV23NOV178)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の腫瘍コンパニオン診断市場（2023-2030）：製品・サービス別、技術別（IHC、NGS）、疾患種類別（乳がん、白血病）、エンドユーザー別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の網膜静脈閉塞症治療市場（2023-2030）：エンドユーザー別（小売薬局、病院・診療所）、疾患種類別（CRVO、BRVO）、治療薬別（抗VEGF薬、副腎皮質ステロイド薬）、地域別
  • 世界の核酸治療薬CDMO市場（2023-2030）：種類別、サービス別（プロセス開発・最適化、製造サービス）、エンドユーザー別、用途別、地域別
  • 世界のラットモデル市場（2023-2030）：種類別（交配種、ノックアウト）、技術別（胚性幹細胞、マイクロインジェクション）、サービス別、用途別、最終用途別、地域別
  • 世界の感染症治療薬市場2023-2030：疾患種類別（HIV、肝炎、インフルエンザ、結核、マラリア、HPV）、エンドユーザー別（病院、診療所）、地域別
  • 世界のバーチャルイベント市場（2023-2030）：イベント種類別、サービス別、施設規模別、エンドユーザー別、用途別、産業別、使用例別、地域別
  • 世界のスマートビルディング市場（2023-2030）：ソリューション別（安全・セキュリティ管理、エネルギー管理）、サービス別（コンサルティング、インプリメンテーション）、エンドユーザー別、地域別
  • 世界のプロテイナーゼK市場（2023-2030）：形態別（粉末、液体）、治療領域別（感染症、神経、腫瘍、循環器）、用途別、エンドユーザー別、地域別
  • 世界のDNAシーケンス市場2023-2030：製品・サービス別（消耗品、機器）、用途別（腫瘍学、HLAタイピング）、技術別、ワークフロー別、エンドユーザー別、地域別
  • 世界の呼吸器合胞体ウイルス（RSV）診断市場（2023-2030）：製品別（DFA、RADT、分子診断、クロマトグラフィー免疫測定）、エンドユーザー別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆